COLLPLANT: POSITIVE RESULTS FOR TENDINOPATHY PRODUCT (Orthopedics This Week)
CollPlant website
CollPlant Ltd., an Israeli regenerative medicine company, is announcing good things for its tendinopathy treatment product, VergenixSTR. The company, which is on schedule to receive CE mark approval for this product in the third quarter of 2016, uses plant-based technology.
As indicated in the August 17, 2016 news release, “The prospective, open label, single-arm trial was conducted at three leading Israeli hospitals (Meir Medical Center, Assaf Harofeh Medical Center and Hadassah Hospital), and the trial’s objective was to demonstrate the safety and performance of VergenixSTR in 40 patients suffering from inflammation of the elbow tendon, commonly referred to as tennis elbow. All patients were followed for a total of six months after a single treatment. Product performance was assessed by measuring reduction in pain and recovery of motion, as reported by the specific Patient Related Tennis Elbow Evaluation questionnaire (“PRTEE”).”
“At three months following treatment, VergenixSTR patients (N=39) reported an average PRTEE score improvement of 51% over baseline. At six-month follow-up, Ve...
